New hope for wet AMD patients: fewer injections with higher dose?
NCT ID NCT07423429
First seen Feb 26, 2026 · Last updated May 16, 2026 · Updated 13 times
Summary
This study looks at whether a higher dose (8 mg) of the drug aflibercept can help people with wet age-related macular degeneration (AMD) go longer between eye injections. Wet AMD is a leading cause of vision loss in older adults, and current treatments often require frequent injections. Researchers will review medical records of 100 adults who switched to this higher dose to see if it safely extends the time between treatments and reduces the overall treatment burden.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EXUDATIVE AGE-RELATED MACULAR DEGENERATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.